Exploring the potential of multiomics liquid biopsy testing in the clinical setting of lung cancer
Cytopathology · 2024-11 · 35 (6) · 664-670
DOI: 10.1111/cyt.13396 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cytopathology, online erschienen am 01.06.2024. Verfasst von Andrea Gottardo und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Precision Medicine in Medical, Surgical and Critical Care (Me.Pre.C.C.), University of Palermo, Palermo, Italy. Hauptthemen laut MEDLINE: Lung Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 52 Literaturangaben.
Abstract (Originalsprache)
The transformative role of artificial intelligence (AI) and multiomics could enhance the diagnostic and prognostic capabilities of liquid biopsy (LB) for lung cancer (LC). Despite advances, the transition from tissue biopsies to more sophisticated, non‐invasive methods like LB has been impeded by challenges such as the heterogeneity of biomarkers and the low concentration of tumour‐related analytes. The advent of multiomics – enabled by deep learning algorithms – offers a solution by allowing the simultaneous analysis of various analytes across multiple biological fluids, presenting a paradigm shift in cancer diagnostics. Through multi‐marker, multi‐analyte and multi‐source approaches, this review showcases how AI and multiomics are identifying clinically valuable biomarker combinations that correlate with patients' health statuses. However, the path towards clinical implementation is fraught with challenges, including study reproducibility and lack of methodological standardization, thus necessitating urgent solutions to solve these common issues.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Precision Medicine in Medical, Surgical and Critical Care (Me.Pre.C.C.), University of Palermo, Palermo, Italy.
- A.R.N.A.S. Hospital Di Cristina, Palermo, Italy.
- Department of Biomedicine, Neuroscience and Advanced Diagnostic (Bi.N.D.), University of Palermo, Palermo, Italy.
ORCID-Profile: Andrea Gottardo, Clarissa Mujacic, Antonio Russo
Zitieren
APA
Gottardo, A., Russo, T. D. B., Perez, A., Bono, M., Di Giovanni, E., Di Marco, E., Siino, R., Bannera, C. F., Mujacic, C., Vitale, M. C., Contino, S., Iannì, G., Busuito, G., Iacono, F., Incorvaia, L., Badalamenti, G., Galvano, A., Russo, A., Bazan, V., & Gristina, V. (2024). Exploring the potential of multiomics liquid biopsy testing in the clinical setting of lung cancer. Cytopathology, 35(6), 664-670. https://doi.org/10.1111/cyt.13396
Vancouver
Gottardo A, Russo TDB, Perez A, Bono M, Di Giovanni E, Di Marco E, et al. Exploring the potential of multiomics liquid biopsy testing in the clinical setting of lung cancer. Cytopathology. 2024;35(6):664-670. doi:10.1111/cyt.13396
BibTeX
@article{Gottardo2024,
author = {Gottardo, Andrea and Russo, Tancredi Didier Bazan and Perez, Alessandro and Bono, Marco and Di Giovanni, Emilia and Di Marco, Enrico and Siino, Rita and Bannera, Carla Ferrante and Mujacic, Clarissa and Vitale, Maria Concetta and Contino, Silvia and Iannì, Giuliana and Busuito, Giulia and Iacono, Federica and Incorvaia, Lorena and Badalamenti, Giuseppe and Galvano, Antonio and Russo, Antonio and Bazan, Viviana and Gristina, Valerio},
title = {Exploring the potential of multiomics liquid biopsy testing in the clinical setting of lung cancer},
journal = {Cytopathology},
year = {2024},
volume = {35},
number = {6},
pages = {664--670},
doi = {10.1111/cyt.13396}
}
EUVIMED